Iranian
Biomedical Journal
Volume 29, Issue 3 (5-2025)
IBJ 2025, 29(3): 159-166 |
Back to browse issues page
Ethics code: IR.TUMS.CHMC.REC.1400.058
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Keshavarz-Fathi M, Darbeheshti F, Makuku R, Pezeshki P S, Seyedmirzaei H, Mansoori Y, et al . Upregulation of CircCSPP1, CircNRIP1, and CircSMAD2 in Breast Cancer and Their Potential as Diagnostic Biomarkers. IBJ 2025; 29 (3) :159-166
URL: http://ibj.pasteur.ac.ir/article-1-4945-en.html
URL: http://ibj.pasteur.ac.ir/article-1-4945-en.html
Mahsa Keshavarz-Fathi 
, Farzaneh Darbeheshti , Rangarirai Makuku , Parmida Sadat Pezeshki , Homa Seyedmirzaei , Yaser Mansoori , Ali Mohammad Mosadeghrad , Nima Rezaei *
, Farzaneh Darbeheshti , Rangarirai Makuku , Parmida Sadat Pezeshki , Homa Seyedmirzaei , Yaser Mansoori , Ali Mohammad Mosadeghrad , Nima Rezaei *
Abstract:
Background: Identifying novel diagnostic biomarkers with stable structures, such as circulating circular RNAs (circRNAs) can improve the early detection and management of BC. Herein, we conducted this study to analyze the expression profile of four circRNAs, including circCSPP1 (hsa_circ_0001806), circNRIP1 (hsa_circ_0004771), circSMAD2 (hsa_circ_0000847), and circFOXP1 (hsa_circ_0008234) in BC.
Methods: Tumor tissues and adjacent normal tissues were obtained from patients with sporadic breast cancer (BC). Divergent primers were designed to amplify the target transcripts using quantitative real-time PCR. The expression profiles of circRNAs were analyzed in tumor and adjacent normal tissues. Sanger sequencing was performed to confirm the back-splicing junctions of circRNAs. ROC curves were generated to assess the potential of the mentioned RNAs as diagnostic biomarkers.
Results: We observed a significant upregulation of circCSPP1, circNRIP1, and circSMAD2 in tumor tissue compared to adjacent normal tissues. Among them, circCSPP1 was the most highly upregulated one in tumor samples from 39 patients. Expression of circCSPP1 was significantly higher in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, human epidermal growth factor receptor-2 (HER2)-negative, and triple-negatives compared to ER-positive, PR-positive, HER2-positive, and non-triple-negative ones. Expression of circNRIP1 was also significantly elevated in the ER-negative and the triple-negative subgroups. These three circRNAs also displayed a desirable potential as diagnostic biomarkers.
Conclusion: This is the first paper that reports the upregulation of circCSPP1 and circSMAD2 in BC and upregulation of circCSPP1 and circNRIP1 in the triple-negative subgroup. Our findings suggest that circCSPP1, circNRIP1, and circSMAD2 may serve as promising diagnostic biomarkers for BC. Identifying the downstream pathways regulated by these circRNAs could lead to the discovery of new therapeutic targets.
Methods: Tumor tissues and adjacent normal tissues were obtained from patients with sporadic breast cancer (BC). Divergent primers were designed to amplify the target transcripts using quantitative real-time PCR. The expression profiles of circRNAs were analyzed in tumor and adjacent normal tissues. Sanger sequencing was performed to confirm the back-splicing junctions of circRNAs. ROC curves were generated to assess the potential of the mentioned RNAs as diagnostic biomarkers.
Results: We observed a significant upregulation of circCSPP1, circNRIP1, and circSMAD2 in tumor tissue compared to adjacent normal tissues. Among them, circCSPP1 was the most highly upregulated one in tumor samples from 39 patients. Expression of circCSPP1 was significantly higher in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, human epidermal growth factor receptor-2 (HER2)-negative, and triple-negatives compared to ER-positive, PR-positive, HER2-positive, and non-triple-negative ones. Expression of circNRIP1 was also significantly elevated in the ER-negative and the triple-negative subgroups. These three circRNAs also displayed a desirable potential as diagnostic biomarkers.
Conclusion: This is the first paper that reports the upregulation of circCSPP1 and circSMAD2 in BC and upregulation of circCSPP1 and circNRIP1 in the triple-negative subgroup. Our findings suggest that circCSPP1, circNRIP1, and circSMAD2 may serve as promising diagnostic biomarkers for BC. Identifying the downstream pathways regulated by these circRNAs could lead to the discovery of new therapeutic targets.
Type of Study: Full Length/Original Article |
Subject:
Cancer Biology
References
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. [DOI:10.3322/caac.21834]
2. Shafaghat Z, Radmehr S, Saharkhiz S, Khosrozadeh A, Feiz K, Alkhathami AG, et al. Circular RNA, a molecule with potential chemistry and applications in RNA-based cancer therapeutics: An insight into recent advances. Top Curr Chem (Cham). 2025;383(2):21. [DOI:10.1007/s41061-025-00505-z]
3. Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12(4):381-8. [DOI:10.1080/15476286.2015.1020271]
4. Chen J, Li Y, Zheng Q, Bao C, He J, Chen B, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 2017;388:208-19. [DOI:10.1016/j.canlet.2016.12.006]
5. He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, et al. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017;36:145. [DOI:10.1186/s13046-017-0614-1]
6. Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett. 2018;430:179-92. [DOI:10.1016/j.canlet.2018.05.033]
7. Zeng K, He B, Yang BB, Xu T, Chen X, Xu M, et al. The pro-metastasis effect of circANKS1B in breast cancer. Mol Cancer. 2018;17(1):160. [DOI:10.1186/s12943-018-0914-x]
8. Darbeheshti F, Mahdiannasser M, Noroozi Z, Firoozi Z, Mansoori B, Daraei A, et al. Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator. J Cell Mol Med. 2021;25(24):11322-32. [DOI:10.1111/jcmm.17066]
9. Zhou SY, Chen W, Yang SJ, Xu ZH, Hu JH, Zhang HD, et al. The emerging role of circular RNAs in breast cancer. Biosci Rep. 2019;39(6):BSR20190621. [DOI:10.1042/BSR20190621]
10. Xie R, Tang J, Zhu X, Jiang H. Silencing of hsa_circ_0004771 inhibits proliferation and induces apoptosis in breast cancer through activation of miR-653 by targeting ZEB2 signaling pathway. Biosci Rep. 2019;39(5):BSR20181919. [DOI:10.1042/BSR20181919]
11. Lü L, Sun J, Shi P, Kong W, Xu K, He B, et al. Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer. Oncotarget. 2017;8(27):44096-107. [DOI:10.18632/oncotarget.17307]
12. Kılıç Y, Çelebiler A, Sakızlı M. Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer. Clin Transl Oncol. 2014;16(2):184-90. [DOI:10.1007/s12094-013-1058-5]
13. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-Epidemiology, risk factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021;13(17):4287. [DOI:10.3390/cancers13174287]
14. Wang J, Zhou L, Chen B, Yu Z, Zhang J, Zhang Z, et al. Circular RNA circCSPP1 promotes the occurrence and development of colon cancer by sponging miR-431 and regulating ROCK1 and ZEB1. J Transl Med. 2022;20(1):58. [DOI:10.1186/s12967-022-03240-x]
15. Sun J, Liu J, Zhu Q, Xu F, Kang L, Shi X. Hsa_circ_0001806 acts as a ceRNA to facilitate the stemness of colorectal cancer cells by increasing COL1A1. Onco Targets Ther. 2020;13:6315-27. [DOI:10.2147/OTT.S255485]
16. Wang Q, Shi L, Shi K, Yuan B, Cao G, Kong C, et al. CircCSPP1 functions as a ceRNA to promote colorectal carcinoma cell EMT and liver metastasis by upregulating COL1A1. Front Occol. 2020;16:10:850. [DOI:10.3389/fonc.2020.00850]
17. Li X, Ma N, Zhang Y, Wei H, Zhang H, Pang X, et al. Circular RNA circNRIP1 promotes migration and invasion in cervical cancer by sponging miR-629-3p and regulating the PTP4A1/ERK1/2 pathway. Cell Death Dis. 2020;11(5):399. [DOI:10.1038/s41419-020-2607-9]
18. Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z, et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019;18(1):20. [DOI:10.1186/s12943-018-0935-5]
19. Huang E, Fu J, Yu Q, Xie P, Yang Z, Ji H, et al. CircRNA hsa_circ_0004771 promotes esophageal squamous cell cancer progression via miR-339-5p/CDC25A axis. Epigenomics. 2020;12(7):587-603. [DOI:10.2217/epi-2019-0404]
20. Qin Y, Zheng Y, Huang C, Li Y, Gu M, Wu Q. Knockdown of circSMAD2 inhibits the tumorigenesis of gallbladder cancer through binding with eIF4A3. BMC Cancer. 2021;21(1):1172. [DOI:10.1186/s12885-021-08895-1]
21. Zhang W, Wu G, Sun P, Zhu Y, Zhang H. circ_SMAD2 regulate colorectal cancer cells proliferation through targeting miR-1258/RPN2 signaling pathway. J Cancer. 2021;12(6):1678-86. [DOI:10.7150/jca.50888]
22. Zhang X, Luo P, Jing W, Zhou H, Liang C, Tu J. circSMAD2 inhibits the epithelial-mesenchymal transition by targeting niR-629 in hepatocellular carcinoma. Onco Targets Ther. 2018;16:11:2853-63. [DOI:10.2147/OTT.S158008]
23. Luo Y, Liu F, Ma J, Fu Y, Gui R. A novel epigenetic regulation of circFoxp1 on Foxp1 in colon cancer cells. Cell Death Dis. 2020;11(9):782. [DOI:10.1038/s41419-020-03007-6]
24. Wang S, Zhang Y, Cai Q, Ma M, Jin LY, Weng M, et al. Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression. Mol Cancer. 2019;18(1):145. [DOI:10.1186/s12943-019-1078-z]
25. Jiang W, He Y, Ma Z, Zhang Y, Zhang C, Zheng N, et al. hsa_circ_0008234 inhibits the progression of lung adenocarcinoma by sponging miR-574-5p. Cell Death Discov. 2021;7(1):123. [DOI:10.1038/s41420-021-00512-1]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |